A nine‐gene signature for predicting the response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park I.J. | - |
dc.contributor.author | Yu Y.S. | - |
dc.contributor.author | Mustafa B. | - |
dc.contributor.author | Park J.Y. | - |
dc.contributor.author | Seo Y.B. | - |
dc.contributor.author | Kim G.-D. | - |
dc.contributor.author | Kim J. | - |
dc.contributor.author | Kim C.M. | - |
dc.contributor.author | Noh H.D. | - |
dc.contributor.author | Hong S.-M. | - |
dc.contributor.author | Kim Y.W. | - |
dc.contributor.author | Kim M.-J. | - |
dc.contributor.author | Ansari A.A. | - |
dc.contributor.author | Buonaguro L. | - |
dc.contributor.author | Ahn S.-M. | - |
dc.contributor.author | Yu C.-S. | - |
dc.date.available | 2020-06-10T05:35:54Z | - |
dc.date.created | 2020-04-16 | - |
dc.date.issued | 2020-04 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/51607 | - |
dc.description.abstract | Preoperative chemoradiotherapy (PCRT) and subsequent surgery is the standard multimodal treatment for locally advanced rectal cancer (LARC), albeit PCRT response varies among the individuals. This creates a dire necessity to identify a predictive model to forecast treatment response outcomes and identify patients who would benefit from PCRT. In this study, we performed a gene expression study using formalin‐fixed paraffin‐embedded (FFPE) tumor biopsy samples from 156 LARC patients (training cohort n = 60; validation cohort n = 96); we identified the nine‐gene signature (FGFR3, GNA11, H3F3A, IL12A, IL1R1, IL2RB, NKD1, SGK2, and SPRY2) that distinctively differentiated responders from non‐responders in the training cohort (accuracy = 86.9%, specificity = 84.8%, sensitivity = 81.5%) as well as in an independent validation cohort (accuracy = 81.0%, specificity = 79.4%, sensitivity = 82.3%). The signature was independent of all pathological and clinical features and was robust in predicting PCRT response. It is readily applicable to the clinical setting using FFPE samples and Food and Drug Administration (FDA) approved hardware and reagents. Predicting the response to PCRT may aid in tailored therapies for respective responders to PCRT and improve the oncologic outcomes for LARC patients. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI AG | - |
dc.relation.isPartOf | Cancers | - |
dc.title | A nine‐gene signature for predicting the response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000535587400030 | - |
dc.identifier.doi | 10.3390/cancers12040800 | - |
dc.identifier.bibliographicCitation | Cancers, v.12, no.4 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85082750801 | - |
dc.citation.title | Cancers | - |
dc.citation.volume | 12 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Mustafa B. | - |
dc.contributor.affiliatedAuthor | Ansari A.A. | - |
dc.contributor.affiliatedAuthor | Ahn S.-M. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Biomarker | - |
dc.subject.keywordAuthor | Locally advanced rectal cancer | - |
dc.subject.keywordAuthor | NanoString analysis | - |
dc.subject.keywordAuthor | Preoperative chemoradiotherapy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.